Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2015
Event: Entry into a Material Definitive Agreement regarding an amendment to the Company's 2013 Amended and Restated Stock Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stock plan amendments rather than financial performance.
Material Changes
The Board of Directors approved an amendment to the 2013 Amended and Restated Stock Plan effective December 15, 2015. The primary material change is the elimination of the provision that previously allowed the Board or its committee to reprice or exchange options granted under the plan for a lower exercise price.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the terms of the stock plan amendment.
Investor Verification Checklist
- Verify the full text of the Second Amendment to the 2013 Amended and Restated Stock Plan (Exhibit 10.1) to confirm the scope of the repricing restriction.
- Confirm the impact of this amendment on existing option holders and future equity compensation strategies.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.